Transgene Biotek Ltd
₹ 2.67
3.09%
16 Feb
- close price
About
Incorporated in 1990, Transgene Biotek Ltd
is in the business of Research & Development[1]
Key Points
- Market Cap ₹ 20.2 Cr.
- Current Price ₹ 2.67
- High / Low ₹ 5.26 / 1.83
- Stock P/E
- Book Value ₹ 1.22
- Dividend Yield 0.00 %
- ROCE -1.75 %
- ROE -6.56 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 23.6%
- Company has a low return on equity of -20.5% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Loading peers table ...
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.98 | 0.30 | 0.18 | 0.28 | 0.12 | 0.07 | 0.00 | 0.17 | 0.09 | 0.06 | 0.23 | 0.26 | 0.23 | |
| 2.81 | 1.90 | 1.32 | 2.84 | 2.22 | 0.75 | 0.87 | 0.70 | 0.55 | 0.68 | 0.83 | 1.38 | 1.03 | |
| Operating Profit | -1.83 | -1.60 | -1.14 | -2.56 | -2.10 | -0.68 | -0.87 | -0.53 | -0.46 | -0.62 | -0.60 | -1.12 | -0.80 |
| OPM % | -186.73% | -533.33% | -633.33% | -914.29% | -1,750.00% | -971.43% | -311.76% | -511.11% | -1,033.33% | -260.87% | -430.77% | -347.83% | |
| -114.37 | 0.01 | 0.17 | 0.66 | 7.37 | 2.04 | 0.18 | 0.27 | 0.21 | 0.18 | 0.18 | 0.78 | 0.04 | |
| Interest | 0.00 | 0.36 | 0.07 | 0.43 | 1.03 | 0.26 | 0.38 | 0.27 | 0.23 | 0.62 | 0.14 | 0.24 | 0.97 |
| Depreciation | 17.22 | 17.18 | 20.50 | 17.53 | 9.89 | 9.89 | 9.90 | 9.91 | 9.92 | 4.95 | 0.09 | 0.09 | 0.17 |
| Profit before tax | -133.42 | -19.13 | -21.54 | -19.86 | -5.65 | -8.79 | -10.97 | -10.44 | -10.40 | -6.01 | -0.65 | -0.67 | -1.90 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 13.98% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| -133.41 | -19.14 | -21.54 | -19.86 | -6.44 | -8.79 | -10.96 | -10.43 | -10.40 | -6.01 | -0.66 | -0.68 | -1.90 | |
| EPS in Rs | -17.61 | -2.53 | -2.84 | -2.62 | -0.85 | -1.16 | -1.45 | -1.38 | -1.37 | -0.79 | -0.09 | -0.09 | -0.25 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | % |
| 3 Years: | 42% |
| TTM: | -4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 14% |
| 3 Years: | 25% |
| TTM: | -726% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | -7% |
| 3 Years: | 0% |
| 1 Year: | -39% |
| Return on Equity | |
|---|---|
| 10 Years: | -19% |
| 5 Years: | -34% |
| 3 Years: | -21% |
| Last Year: | -7% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 |
| Reserves | 130.20 | 115.62 | 98.67 | -16.90 | -23.34 | -32.13 | -43.10 | -53.53 | -58.39 | -64.40 | -65.06 | -65.74 | -66.56 |
| 13.06 | 14.43 | 15.28 | 16.01 | 9.84 | 9.14 | 10.33 | 11.33 | 12.01 | 13.11 | 14.00 | 14.52 | 16.50 | |
| 139.32 | 137.95 | 123.27 | 123.18 | 124.28 | 123.77 | 123.75 | 123.31 | 117.71 | 117.87 | 117.62 | 119.54 | 118.04 | |
| Total Liabilities | 358.35 | 343.77 | 312.99 | 198.06 | 186.55 | 176.55 | 166.75 | 156.88 | 147.10 | 142.35 | 142.33 | 144.09 | 143.75 |
| 180.58 | 163.40 | 140.95 | 61.16 | 50.97 | 41.10 | 31.20 | 21.32 | 11.40 | 6.45 | 6.36 | 7.96 | 9.73 | |
| CWIP | 0.29 | 0.29 | 0.29 | 2.04 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 |
| 177.48 | 180.08 | 171.75 | 134.86 | 133.71 | 133.58 | 133.68 | 133.69 | 133.73 | 133.93 | 134.00 | 134.16 | 133.92 | |
| Total Assets | 358.35 | 343.77 | 312.99 | 198.06 | 186.55 | 176.55 | 166.75 | 156.88 | 147.10 | 142.35 | 142.33 | 144.09 | 143.75 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.11 | 3.52 | 6.47 | 0.02 | -0.63 | -1.74 | 0.14 | 0.01 | 0.10 | 0.00 | 0.00 | 1.20 | |
| 1.45 | -4.57 | -6.47 | 0.00 | 3.05 | 1.74 | 0.00 | -0.03 | -0.10 | -0.01 | 0.00 | -1.70 | |
| 0.60 | 1.03 | 0.00 | 0.00 | -2.37 | 0.00 | -0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.78 | |
| Net Cash Flow | -0.05 | -0.02 | 0.00 | 0.02 | 0.05 | 0.00 | -0.06 | -0.01 | 0.00 | -0.01 | 0.00 | 0.28 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 6,797.19 | 19,953.33 | 3,325.56 | 13.04 | 30.42 | 52.14 | 21.47 | 40.56 | 60.83 | 15.87 | 14.04 | |
| Inventory Days | 106.46 | 365.00 | 365.00 | 1,460.00 | 121.67 | 156.43 | ||||||
| Days Payable | 25,975.83 | 5,018.75 | 3,528.33 | 13,870.00 | 1,460.00 | 1,199.29 | ||||||
| Cash Conversion Cycle | -19,072.18 | 19,953.33 | 3,325.56 | 13.04 | -4,623.33 | -3,111.19 | -1,316.86 | 40.56 | -982.02 | 15.87 | 14.04 | |
| Working Capital Days | -2,007.50 | -8,528.83 | -16,019.44 | -14,339.29 | -39,967.50 | -62,519.29 | -29,092.65 | -34,593.89 | -57,365.83 | -15,933.04 | -16,509.23 | |
| ROCE % | -6.48% | -8.83% | -10.86% | -14.69% | -10.97% | -17.91% | -22.11% | -26.56% | -32.31% | -20.01% | -2.07% | -1.75% |
Documents
Announcements
- Dear Sir/Madam, This Has Reference To Our Letter Dated January 28 2026. 1) The Board Has Considered And Approved The Unaudited Consolidated & Stand-Alone Financial Results Of The Company, For The Quarter Ended 31.12.2025 In Accordance With The Indian Accounting Standards (IND-AS) As Per Companies (Indian Accounting Standards) Rules, 2015. 2) Limited Review Report On The Unaudited Standalone And Consolidated Financial Results Of The Company, For The Quarter Ended 31.12.2025 Has Also Been Approved. The Meeting Commenced At 11:00 A.M. And Concluded At 11:45 A.M. 13 Feb
-
Board Meeting Outcome for Outcome Of Board Meeting
13 Feb - Q3 FY2026 unaudited results: revenue Rs5.45L, quarter loss Rs37.38L, YTD loss Rs119.59L
-
Declaration Under Clause 36 Of Listing Agreement With BSE
PROHIBITORY ORDER NO. RRD/SRO/1166/2026/1 - SEBI
3 Feb - SEBI recovery order Jan 19, 2026 seeking Rs.38 lakh; bank accounts frozen, assets prohibited.
-
Board Meeting Intimation for Intimation Of The Board Meeting To Be Held On Friday, 13Th February, 2026
28 Jan - Board meeting on 13-Feb-2026 to approve unaudited standalone and consolidated results for quarter ended 31-Dec-2025.
-
Statement Of Deviation & Variation
12 Jan - Reg 32(1) not applicable for quarter ended 31-Dec-2025; no public/rights/preferential issues.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
TBL started as a Biotechnology company engaged in the manufacturing and selling diagnostic kits. The company expanded to biotech research, including the research and development of vaccines, oncology, New drug delivery technologies etc. Currently, the company has a product and technology portfolio covering Oncology, Oral Drug Delivery and Bio-generics.